International Journal of Radiation Oncology*Biology*Physics
Clinical investigationProstateSecond malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up
Introduction
Because of a trend toward diagnosing prostate cancer at a younger age and earlier stage (1, 2) and increasingly successful treatment options, (3) the number of prostate cancer survivors is expected to continue to rise. The success of radiation therapy (RT) has been an important factor in increasing rates of survivorship, but one legitimate long-term concern may be radiation-associated malignancies, particularly secondary solid tumors (4). Some estimates of second malignancy after RT for prostate cancer include a small but statistically significant added risk of second bladder cancers (5, 6) and colorectal cancers (5, 7, 8) in patients with long follow-up. One critical factor in the development of secondary cancers appears to be the volume of tissue that is radiated above a threshold dose (9). However, because estimates of the risk of second malignancy after RT are often generated from large datasets that lack the technical details of treatment to obtain sufficient statistical power, risk cannot be easily described according to the volume radiated. The goal of this study is to report the rate of bladder and colorectal cancers in patients with 15 years of potential follow-up who were treated with brachytherapy for prostate cancer, with or without supplemental external beam radiation therapy.
Section snippets
Methods and materials
This review included 348 patients with biopsy-proven adenocarcinoma of the prostate who were treated with prostate brachytherapy at the Seattle Prostate Institute from January 1987 to January 1994. Two subsets of patients included: 125 consecutive patients treated with an Iodine-125 (I-125) implant as monotherapy between 1988 and 1990 (10) and 223 consecutive patients treated with external beam RT followed by an I-125 or Palladium-103 implant between 1987 and 1994 (11). Patient characteristics
Results
Overall, 15 of 348 patients (4.3%) developed a bladder (n = 11), colorectal (n = 3), or prostatic urethra (n = 1) carcinoma five or more years after RT (median time, 9 years 6 months), at a median age of 80 years. Thirteen of 223 patients who received supplemental RT (5.8%) developed a bladder or colorectal malignancy compared with 2 of 125 patients who received brachytherapy alone (1.6%, p = 0.0623). Details of each potential radiation-associated secondary solid tumor are listed in Table 2.
Discussion
Over the last decade, treatment for prostate cancer has become increasingly successful, in no small part related to earlier diagnosis with PSA screening. RT has led to high rates of curability for all stages of disease (10, 11, 17, 18), with dose, volume treated, and use of hormonal therapy tailored to the risk level of the patient. With control rates and survivorship that approach 100% in some large series (19, 20, 21), long-term complications become an increasingly important factor for the
Conclusions
The incidence of developing a secondary bladder cancer five or more years after brachytherapy, with or without supplemental external beam RT, was slightly higher (absolute excess risk 35 bladder cancers per 10,000 patients) than age-matched SEER data indicates. Patients should be followed after successful treatment for prostate cancer with the understanding that there may be a small risk of developing a second solid tumor that is radiation-associated, especially in long-term survivors.
References (34)
- et al.
Increased risk of rectal cancer after prostate radiation: A population-based study
Gastroenterology
(2005) - et al.
The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984–2000
Radiother Oncol
(2002) - et al.
Radiation-induced second cancers: The Impact of 3D-CRT and IMRT
Int J Radiat Oncol Biol Phys
(2003) - et al.
10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy
Int J Radiat Oncol Biol Phys
(2001) - et al.
Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience
Int J Radiat Oncol Biol Phys
(2003) - et al.
High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients
Int J Radiat Oncol Biol Phys
(2002) - et al.
Combined modality treatment in the management of high-risk prostate cancer
Int J Radiat Oncol Biol Phys
(2004) - et al.
Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer
Urology
(2004) - et al.
Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy
Int J Radiat Oncol Biol Phys
(2005) - et al.
103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: A 12-year experience from a single group practice
Brachytherapy
(2005)